Similar studies for GEO DataSets (Select 200192974) - GEO DataSets

Links from GEO DataSets

Items: 20

Select item 2001929741.

HMG20B stabilizes interaction of LSD1 with GFI1 on chromatin to confer transcription repression and leukemia cell differentiation block [RNA-seq]

(Submitter supplied) Pharmacologic inhibition of LSD1 induces molecular and morphologic differentiation of blast cells in acute myeloid leukaemia (AML) patients harboring MLL gene translocations. In addition to its demethylase activity, LSD1 has a critical scaffolding function at genomic sites occupied by the SNAG domain transcription repressor GFI1. Importantly, inhibitors block both enzymatic and scaffolding activities, in the latter case by disrupting the protein:protein interaction of GFI1 with LSD1. more...

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platform:: GPL18573
6 Samples

Download data: BW

Series

Accession:: GSE192974

ID:: 200192974

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2001929752.

HMG20B stabilizes interaction of LSD1 with GFI1 on chromatin to confer transcription repression and leukemia cell differentiation block

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing

Platform:: GPL18573
20 Samples

Download data: BW

Series

Accession:: GSE192975

ID:: 200192975

PubMed Full text in PMC Similar studies

Select item 2001929733.

HMG20B stabilizes interaction of LSD1 with GFI1 on chromatin to confer transcription repression and leukemia cell differentiation block [ChIP-seq II]

Organism:: Homo sapiens

Type:: Genome binding/occupancy profiling by high throughput sequencing

Platform:: GPL18573
8 Samples

Download data: BW

Series

Accession:: GSE192973

ID:: 200192973

PubMed Full text in PMC Similar studies

Select item 2001929724.

HMG20B stabilizes interaction of LSD1 with GFI1 on chromatin to confer transcription repression and leukemia cell differentiation block [ChIP-seq I]

Organism:: Homo sapiens

Type:: Genome binding/occupancy profiling by high throughput sequencing

Platform:: GPL18573
6 Samples

Download data: BW

Series

Accession:: GSE192972

ID:: 200192972

PubMed Full text in PMC Similar studies

Select item 2001120745.

Inhibitors of LSD1 target demethylase-independent activity to induce differentiation in acute myeloid leukemia [anti-H3K9 ac, anti-H3K27, RCOR1, SPI1, and MLL4 ChIP-Seq]

(Submitter supplied) To determine whether changes in histone modifications directly correlate with changes in transcription, THP1 AML cells were treated with a potent and selective LSD1 inhibitor (OG86, 250nM) and then subjected to concomitant RNA sequencing (RNAseq) and ChIP sequencing (ChIPseq) for histone acetylation modifications, RCOR1, SPI1 and MLL4.

Organism:: Homo sapiens

Type:: Genome binding/occupancy profiling by high throughput sequencing

Platform:: GPL18573
10 Samples

Download data: BW

Series

Accession:: GSE112074

ID:: 200112074

PubMed Full text in PMC Similar studies SRA Run Selector

Select item 2000907706.

Inhibitors of LSD1 target demethylase-independent activity to induce differentiation in acute myeloid leukemia [ATAC-Seq]

(Submitter supplied) To identify regions of genome accessibility influenced by LSD1 inhibition, THP1 AML cells were subjected to ATAC sequencing.

Organism:: Homo sapiens

Type:: Genome binding/occupancy profiling by high throughput sequencing

Platform:: GPL18573
2 Samples

Download data: TXT

Series

Accession:: GSE90770

ID:: 200090770

PubMed Full text in PMC Similar studies SRA Run Selector

Select item 2000907697.

Inhibitors of LSD1 target demethylase-independent activity to induce differentiation in acute myeloid leukemia [anti-LSD1, MYB, and GFI1 ChIP-Seq]

(Submitter supplied) To identify genomic binding regions, THP1 AML cells were subjected to ChIP sequencing (ChIPseq) using anti-LSD1, MYB or GFI1 antibodies.

Organism:: Homo sapiens

Type:: Genome binding/occupancy profiling by high throughput sequencing

Platform:: GPL18573
6 Samples

Download data: TXT

Series

Accession:: GSE90769

ID:: 200090769

PubMed Full text in PMC Similar studies SRA Run Selector

Select item 2000632228.

Inhibitors of LSD1 target demethylase-independent activity to induce differentiation in acute myeloid leukemia

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing

Platforms:: GPL16558 GPL18573 GPL16791
28 Samples

Download data: BW, TXT

Series

Accession:: GSE63222

ID:: 200063222

PubMed Full text in PMC Similar studies

Select item 2000632189.

Inhibitors of LSD1 target demethylase-independent activity to induce differentiation in acute myeloid leukemia [ChIP-Seq: histone modifications]

(Submitter supplied) To determine whether changes in histone modifications directly correlate with changes in transcription, THP1 AML cells were treated with a potent and selective LSD1 inhibitor (OG86) and then subjected to concomitant RNA sequencing (RNAseq) and ChIP sequencing (ChIPseq) for monomethyl-, dimethyl- and trimethyl histone H3 modifications.

Organism:: Homo sapiens

Type:: Genome binding/occupancy profiling by high throughput sequencing

Platform:: GPL16791
6 Samples

Download data: TXT

Series

Accession:: GSE63218

ID:: 200063218

PubMed Full text in PMC Similar studies SRA Run Selector

Select item 20006321710.

Inhibitors of LSD1 target demethylase-independent activity to induce differentiation in acute myeloid leukemia [RNA-Seq experiments]

(Submitter supplied) To determine whether changes in histone modifications directly correlate with changes in transcription, THP1 AML cells were treated with a potent and selective LSD1 inhibitor (OG86) and then subjected to concomitant RNA sequencing (RNAseq) and ChIP sequencing (ChIPseq) for monomethyl-, dimethyl- and trimethyl histone H3 modifications.

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platform:: GPL16558
4 Samples

Download data: TXT

Series

Accession:: GSE63217

ID:: 200063217

PubMed Full text in PMC Similar studies Analyze with GEO2R SRA Run Selector

Select item 20011017811.

LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML

(Submitter supplied) Lsd1KO and ATRA treatment in Hoxa9/Meis1- and MN1-transformed myeloid progenitor cells LSD1 has emerged as a promising epigenetic target in the treatment of acute myeloid leukemia (AML). Inhibition of LSD1 has been shown to induce differentiation and facilitate the responsiveness of AML cells to all-trans retinoic acid. We used two murine AML models based on retroviral overexpression of Hoxa9/Meis1 (H9M) or MN1 to study the effect of Lsd1 knockout in AML. more...

Organism:: Mus musculus

Type:: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing

Platforms:: GPL21103 GPL17021
26 Samples

Download data: BED, TXT, XLSX

Series

Accession:: GSE110178

ID:: 200110178

PubMed Similar studies SRA Run Selector

Select item 20014541012.

Single-cell RNA-seq of AML patient bone marrow treated with INCB059872, azacitidine, or combination

(Submitter supplied) INCB059872 is a selective irreversible inhibitor of Lysine-Specific Demethylase 1 (LSD1) that is in phase 1 clinical trials in hematopoietic malignancies. We evaluated a pre-treatment bone marrow sample of a patient who showed a clinical response to INCB059872 + azacitidine treatment. Single-cell RNA-sequencing (scRNA-seq) showed that INCB059872 caused a shift in gene expression that was associated with GFI1/GFI1B regulation.

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platform:: GPL24676
8 Samples

Download data: MTX, TSV

Series

Accession:: GSE145410

ID:: 200145410

PubMed Full text in PMC Similar studies SRA Run Selector

Select item 20014527913.

Single-cell RNA-seq: INCB059872 in wild-type murine bone marrow

(Submitter supplied) INCB059872 is a selective irreversible inhibitor of Lysine-Specific Demethylase 1 (LSD1) that is in phase 1 clinical trials in hematopoietic malignancies. Mice treated with INCB059872 had reduced platelet counts within 4 days of treatment. Here, we used single-cell RNA-seq to study the effects of INCB059872 on hematopoietic progenitor populations within wild-type murine bone marrow. Our results showed that INCB059872 triggered accumulation of megakaryocyte early progenitor cells with gene expression hallmarks of stem cells, which may begin to explain the thrombocytopenia observed in patients treated with LSD1 inhibitors.

Organism:: Mus musculus

Type:: Expression profiling by high throughput sequencing

Platform:: GPL24247
9 Samples

Download data: TAR

Series

Accession:: GSE145279

ID:: 200145279

PubMed Full text in PMC Similar studies SRA Run Selector

Select item 20014521114.

RNA-seq of murine megakaryocyte progenitor cells treated with LSD1 inhibitor INCB059872

(Submitter supplied) INCB059872 is a selective irreversible inhibitor of Lysine-Specific Demethylase 1 (LSD1) that is in phase 1 clinical trials in hematopoietic malignancies. We identified a population of cells within murine lineage-negative bone marrow that is expanded after treatment with INCB059872. Here we sorted cells from this population (Lin- Cd41+ Cd200r3-) and performed RNA-seq to measure gene expression changes caused by INCB059872. more...

Organism:: Mus musculus

Type:: Expression profiling by high throughput sequencing

Platform:: GPL24247
6 Samples

Download data: DIFF

Series

Accession:: GSE145211

ID:: 200145211

PubMed Full text in PMC Similar studies SRA Run Selector

Select item 20014516615.

ChIP-seq for histone acetylation and methylation in THP-1 cells treated with LSD1 inhibitor INCB059872

(Submitter supplied) INCB059872 is a selective irreversible inhibitor of Lysine-Specific Demethylase 1 (LSD1) that is in phase 1 clinical trials in hematopoietic malignancies. We performed ChIP-seq for histone modifications to define the earliest regulatory events associated with INCB059872 treatment. Changes in acetylation were more dramatic than changes in methylation, and these changes could be traced back to a loss of CoREST activity at GFI1-regulated targets.

Organism:: Homo sapiens

Type:: Genome binding/occupancy profiling by high throughput sequencing

Platforms:: GPL24676 GPL18573
20 Samples

Download data: BEDGRAPH

Series

Accession:: GSE145166

ID:: 200145166

PubMed Full text in PMC Similar studies SRA Run Selector

Select item 20014510616.

RNA-seq of MV-4-11 or THP-1 cells treated with LSD1 inhibitor INCB059872

(Submitter supplied) INCB059872 is a selective irreversible inhibitor of Lysine-Specific Demethylase 1 (LSD1) that is in phase 1 clinical trials in hematopoietic malignancies. LSD1 inhibition can induce differentiation of acute myeloid leukemia (AML), and here we have used RNA-seq to measure the transcriptional changes caused by INCB059872 in two AML cell lines.

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platform:: GPL21290
14 Samples

Download data: DIFF

Series

Accession:: GSE145106

ID:: 200145106

PubMed Full text in PMC Similar studies Analyze with GEO2R SRA Run Selector

Select item 20014507117.

PRO-seq of THP-1 cells treated with LSD1 inhibitor INCB059872

(Submitter supplied) INCB059872 is a selective irreversible inhibitor of Lysine-Specific Demethylase 1 (LSD1) that is in phase 1 clinical trials in hematopoietic malignancies. We used precision nuclear run-on sequencing (PRO-seq) to define early transcriptional changes associated with INCB059872 treatment. Changes in nascent transcription could be traced back to a loss of CoREST activity resulting in activation of GFI1-regulated targets.

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing; Other

Platform:: GPL18573
8 Samples

Download data: BEDGRAPH

Series

Accession:: GSE145071

ID:: 200145071

PubMed Full text in PMC Similar studies SRA Run Selector

Select item 20012840018.

Differential gene expression profiling by deletion of GFI1 super-enhancer (GFI1-SE-KO) upon treatment of a LSD1 inhibitor NCD38 in HEL cells

(Submitter supplied) Activation of GFI1-super-enhancer (GFI1-SE) by a LSD1 inhibitor NCD38 was relevant to myeloid differentiation and antileukemia effect in human erythroleukemia cells (HEL cells). Thus, we investigated the role of GFI1-SE upon NCD38 treatment in HEL cells. We established three independent sublines with bi-allelic deletion of GFI1-SE (CCE2 #114, #141, and #216) using CRISPR-Cas9 genome editing system in HEL cells and a classical limiting dilution method. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL16686
12 Samples

Download data: CEL, CHP

Series

Accession:: GSE128400

ID:: 200128400

Select item 20012853019.

Targeting the scaffolding role of LSD1(KDM1A) poises acute myeloid leukemia cells for Retinoic Acid induced differentiation

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing

Platforms:: GPL11154 GPL9115
34 Samples

Download data: BED

Series

Accession:: GSE128530

ID:: 200128530

PubMed Full text in PMC Similar studies

Select item 20012852920.

Targeting the scaffolding role of LSD1(KDM1A) poises acute myeloid leukemia cells for Retinoic Acid induced differentiation [RNA-seq]

(Submitter supplied) The histone demethylase LSD1 is deregulated in several tumors, including leukemias, providing the rationale for the clinical use of LSD1 inhibitors . In acute promyelocytic leukemia (APL), pharmacological doses of retinoic acid (RA) induce differentiation of APL cells through degradation of the PML-RAR oncogene. APL cells are resistant to LSD1 inhibition or knock-out, but LSD1 inhibition sensitizes them to physiological doses of RA without altering the stability of PML-RAR, and extends survival of leukemic mice upon RA treatment. more...

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platforms:: GPL9115 GPL11154
9 Samples

Download data: TXT

Series

Accession:: GSE128529

ID:: 200128529

PubMed Full text in PMC Similar studies Analyze with GEO2R SRA Run Selector

GEO DataSets

Functional Genomics Studies

Result Filters

Entry type

Organism

Study type

Author

Attribute name

Publication dates

Custom date range

Additional filters

Send to:

Links from GEO DataSets

Items: 20

Send to:

Supplemental Content

Find related data

Important Links

Recent activity